SCHEMBL12552811

SCHEMBL12552811

CCOC(=O)c1c(C)cc(C)cc1C=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.55
USP2 O75604 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
ALDH1A1 P00352 5/20 0.47
HPGD P15428 2/20 0.46
NR1H2 P55055 1/20 0.46
NR1H3 Q13133 1/20 0.46
ERN1 O75460 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
KMT2A Q03164 4/20 0.43
POLB P06746 1/20 0.43
MEN1 O00255 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12552819 0.85 NR1H2 (0.57) CYP3A4USP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL571273 0.84 CYP3A4 (0.61) CYP3A4USP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL11357629 0.80 CYP3A4 (0.51) CYP3A4USP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL12552740 0.77 CYP3A4 (0.74) CYP3A4USP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL243902 0.77 ERN1 (0.52) CYP3A4SMN1; SMN2TDP1ALDH1A1ERN1
SCHEMBL10935815 0.76 CYP3A4 (0.51) CYP3A4USP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL5651196 0.75 ERN1 (0.56) CYP3A4USP2SMN1; SMN2ALDH1A1NR1H2
SCHEMBL498855 0.75 CYP3A4 (0.50) CYP3A4USP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL12552815 0.75 CYP3A4 (0.51) CYP3A4USP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL30676219 0.74 ATM (0.42) CYP3A4USP2SMN1; SMN2TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130196987-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS EISAI CO., LTD. (JP) 2013-08-01 US disclosed
US-8329742-B2 Macrocyclic compounds useful as pharmaceuticals EISAI CO., LTD. (JP) 2012-12-11 US disclosed
US-20110144101-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS EISAI CO., LTD. (JP) 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144101-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS FLT1, TBXA2R, VEGFA CYP3A4 1204/4885USP2 4728/4885SMN1; SMN2 2503/4885
US-20130196987-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS FLT4, VEGFA, FLT1 CYP3A4 1158/4885USP2 4538/4885SMN1; SMN2 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.